ESMO 2023 Lung Cancer Highlights - Keynote 671 | ALINA | TropionLung01 | Oncology Brothers

In discussion with Dr. Joshua Reuss, covering the ESMO 2023 Lung Cancer Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Reuss:
- Keynote 671 - perioperative approach in non-small cell lung cancer with pembrolizumab and cisplatin based chemo combination, with positive OS data
- ALINA - resectable non-small cell lung cancer pts with ALK positive disease, Alectinib will be the new standard of care given incredible DFS
- TropionLung 01 - Dato-DXd in 2nd line non-small cell lung cancer reports slightly greater PFS when compared to docetaxel
#ESMO #PrecisionMedicine #LungCancer #2023 #cancer #oncology #oncbrothers
Website: www.oncbrothers.com/
Twitter: / oncbrothers
Contact us at [e-mail]

[@brunoramos7083]

Very good review and discussion!